GlassScriptPhysician profile
Tara R Brown
NPI 1659697738
$792.59
in general payments reported to CMS, 2019-2025
20 companies · $68.38 in 2025
The $68.38 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $157 · 2021: $25.86 · 2023: $238 · 2024: $16.20 · 2025: $68.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $111.01 | 2023-2025 | Linzess, Viberzi, Creon |
| Pfizer INC. | $77.97 | 2019-2023 | |
| Astellas Pharma US INC | $68.75 | 2020-2024 | Veozah |
| Amgen INC. | $65.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $55.22 | 2019-2021 | |
| Allergan, INC. | $49.36 | 2019-2020 | |
| Cequr Corporation | $48.10 | 2023 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.66 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $39.58 | 2019-2020 | |
| Glaxosmithkline, LLC. | $36.10 | 2023 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $31.93 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $25.08 | 2020-2021 | |
| Boston Scientific Corporation | $24.32 | 2025 | Watchman Flx |
| Abiomed | $24.01 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.52 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.87 | 2019 | |
| Shire North American Group INC | $14.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.70 | 2020 | |
| Endo Pharmaceuticals INC. | $11.55 | 2019 | |
| Mylan Specialty L.P. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.